SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (223)1/20/1998 3:50:00 PM
From: Rudy Saucillo   of 1494
 
Thanks, John.

Here are 2 additional abstracts supporting the role of memantine as a potential treatment for pathological pain.

I'm "long" and looking forward to the upcoming Phase II results.

Rudy

Neurosci Lett 1995 Sep 29;198(2):115-118

Treatment with the NMDA antagonist memantine attenuates
nociceptive responses to mechanical stimulation in neuropathic
rats.

Carlton SM, Hargett GL

Systemic treatment with the N-methyl-D-aspartate (NMDA)
antagonist memantine (MEM) resulted in a decrease in mechanical
hyperalgesia and mechanical allodynia in neuropathic rats. Bolus
injections of 5, 10 and 20 mg/kg MEM (i.p.) attenuated
withdrawal responses following mechanical stimulation for up to 6
h post-injection while saline had no effect. A more remarkable
effect was observed following chronic treatment with MEM via
mini-osmotic pumps (8 mg/kg per h for 7 days, i.p.), in which
nociceptive responses were decreased during treatment and
remained depressed for 3 days post-treatment. These
antinociceptive effects can be obtained at doses which do not
produce motor dysfunction. The results of this study demonstrate
that MEM has a therapeutic effect on mechanical hyperalgesia and
allodynia and may be considered as an alternative treatment for
pathological pain in the clinical setting.

Neurosci Lett 1995 Feb 24;187(1):17-20

The clinically tested N-methyl-D-aspartate receptor antagonist
memantine blocks and reverses thermal hyperalgesia in a rat model
of painful mononeuropathy.

Eisenberg E, LaCross S, Strassman AM

This study tested the prophylactic and therapeutic efficacy of
memantine (1-amino-3,5-dimethyl-amandate), a clinically tested
N-methyl-D-aspartate (NMDA) antagonist on thermal hyperalgesia
in a rat model of painful mononeuropathy. Persistent hyperalgesia
induced by chronic constrictive injury (CCI) to the sciatic nerve
was significantly reduced for up to 14 days by prophylactic
administration of memantine (3.0 mg/kg) via i.p. implanted
osmotic micropumps for a period of 7 days. Therapeutic i.p.
injections of memantine (10 mg/kg) given on post-injury days 7
and 14 completely reversed existing hyperalgesia for a short
period of 1 h. These results provide evidence that memantine
produces long-term prophylactic and short-term therapeutic effects
on thermal hyperalgesia in a model of painful mononeuropathy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News